Xponance’s Altimmune ALT Stock Holding History

Xponance’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.5K	Buy	18,917 +8,134	+75%	+$24.3K	﹤0.01%	1776
2026 Q1	$33.2K	Buy	+10,783	New	+$45.8K	﹤0.01%	1653

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's ALT Position: Q2 2026 in Review

Xponance increased its Altimmune (ALT) stake by 75% in Q2 2026, buying an estimated $24.3K and bringing the position to 18,917 shares worth $57.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1776.

Xponance first reported a position in ALT in Q1 2026 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

Xponance held 18,917 shares of Altimmune worth $57.5K as of Q2 2026.
Xponance bought 8,134 Altimmune shares in Q2 2026, an estimated $24.3K.
Altimmune made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1776 holding.
Xponance first reported a position in Altimmune in Q1 2026 and has held it in 2 quarters since.
210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.